Publication | Closed Access

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Drug SafetyOncologyMedicineAdverse Drug ReactionPatient SafetyClinical TrialsOutcomes ResearchAdriamycin–cyclophosphamide-based ChemotherapyDrug MonitoringPharmacotherapySide EffectPharmacologyRisk FactorsPhase 3Health Sciences